SGLT2 inhibitors vs. GLP-1 agonists: Comparative progression of renal disease

被引：0
|
作者：
Stevens, Lauren [1 ]
Bowe, Andy [1 ]
Schwab, Phil [1 ]
Tindal, Michael [2 ]
Bloomfield, Andrea [2 ]
机构：
[1] Humana Healthcare Res, Louisville, KY USA
[2] Humana Pharm Solut, Louisville, KY USA
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2021年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
引用
收藏
页码：110 / 110
页数：1
相关论文
共 50 条
  • [31] Major adverse cardiovascular and limb events in people with diabetes treated with GLP-1 receptor agonists vs SGLT2 inhibitors
    Lin, Donna Shu-Han
    Yu, An-Li
    Lo, Hao-Yun
    Lien, Cheng-Wei
    Lee, Jen-Kuang
    Chen, Wen-Jone
    [J]. DIABETOLOGIA, 2022, 65 (12) : 2032 - 2043
  • [32] Major adverse cardiovascular and limb events in people with diabetes treated with GLP-1 receptor agonists vs SGLT2 inhibitors
    Donna Shu-Han Lin
    An-Li Yu
    Hao-Yun Lo
    Cheng-Wei Lien
    Jen-Kuang Lee
    Wen-Jone Chen
    [J]. Diabetologia, 2022, 65 : 2032 - 2043
  • [33] The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system
    Schernthaner, Guntram
    Mogensen, Carl Erik
    Schernthaner, Gerit-Holger
    [J]. DIABETES & VASCULAR DISEASE RESEARCH, 2014, 11 (05): : 306 - 323
  • [34] Use of SGLT2 Inhibitors vs GLP-1 RAs and Anemia in Patients With Diabetes and CKD
    Hu, Jia-Chian
    Shao, Shih-Chieh
    Tsai, Daniel Hsiang-Te
    Chuang, Albert Tzu-Ming
    Liu, Kuan-Hung
    Lai, Edward Chia-Cheng
    [J]. JAMA NETWORK OPEN, 2024, 7 (03) : E240946
  • [35] GLP-1 agonists and SGLT-2 inhibitors in adults with sickle cell disease
    Sun, Ryan
    Srivastava, Anand
    Derebail, Vimal K.
    Han, Jin
    Molokie, Robert E.
    Gordeuk, Victor
    Saraf, Santosh L.
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2024, 99 (08) : 1610 - 1612
  • [36] In CV disease, GLP-1 RAs and SGLT2 inhibitors reduce CV mortality
    Kelsey, Michelle D.
    Newby, L. Kristin
    [J]. ANNALS OF INTERNAL MEDICINE, 2022, 175 (03) : JC26 - JC26
  • [37] Positioning of GLP-1 receptor agonists and SGLT2 inhibitors: what do the guidelines say in diabetes?
    Darmon, P.
    [J]. CORRESPONDANCES EN METABOLISMES HORMONES DIABETES ET NUTRITION, 2023, 27 (02): : 62 - 65
  • [38] Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Renin-Angiotensin-Aldosterone System
    Puglisi, Soraya
    Rossini, Alessandro
    Poli, Roberta
    Dughera, Francesca
    Pia, Anna
    Terzolo, Massimo
    Reimondo, Giuseppe
    [J]. FRONTIERS IN ENDOCRINOLOGY, 2021, 12
  • [39] SGLT2 inhibitors and GLP-1 receptor agonists: which is the best anti-frailty drug?
    Mone, Pasquale
    Ciccarelli, Michele
    Jankauskas, Stanislovas S.
    Guerra, Germano
    Vecchione, Carmine
    Visco, Valeria
    Santulli, Gaetano
    [J]. LANCET HEALTHY LONGEVITY, 2024, 5 (09):
  • [40] Relation between Combination Therapy with SGLT2 Inhibitors and GLP-1 Receptor Agonists and Renal Functions among Japanese Diabetics
    Toyoda, Masao
    Kobayashi, Kazuo
    [J]. DIABETES, 2023, 72
12345